LIDDS AB (publ) announced that Matthew Lindon will assume the role of acting Chief Executive Officer for LIDDS, effective August 1st, 2023, succeeding Anders Månsson. In addition to his role as Chief Scientific Officer for LIDDS, Matthew Lindon will take over the role as CEO on an interim basis from August 1st. Matthew joined LIDDS as CSO in March 2022 with over 20 years of drug discovery and development experience in global pharmaceutical R&D from AstraZeneca, GlaxoSmithKline and Merck. Over the last twelve months he has worked closely with out-going CEO, Anders Månsson to focus LIDDS' business and drive forward a strong business development strategy.
Anders will remain with LIDDS until August 31st to ensure a smooth transition.